Clinical Trials Sponsored by Avilex Pharma

Total 8346 results

Avilex Pharma

Completed

A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144

Tolerance | Safety Issues

Finland
Aneira Pharma, Inc.
DataPharm Australia, CMAX Clinical Research, Agilex Australia

Not yet recruiting

Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia

Androgenetic Alopecia
Avigen

Terminated

Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury

Muscle Spasticity

United States, Canada
Avigen

Completed

AV650 Drug-Drug Interaction Study

Healthy

United States
Avigen

Completed

Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650

Healthy Subjects

United States
Avigen

Terminated

Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis

Muscle Spasticity

Czech Republic, Ukraine, Germany, Russian Federation, Serbia
Avigen

Completed

Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain

Diabetic Neuropathy

Australia
Avulux, Inc.

Completed

Optical Treatment of Migraines Using the Avulux™ Optical Filter in the Form of Spectacle Lenses.

Migraine

United States
Scilex Ltd.

Unknown

Enhanced Safety Aesthetic Laser System

Hirsutism | Rhytides | Hypertrichosis | Telangiectases

Israel
Scilex Ltd.

Unknown

Enhanced Safety Laser Hair Removal System

Hirsutism | Hypertrichosis

Israel
Aminex Therapeutics, Inc.

Recruiting

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Melanoma | Cervical Cancer | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Solid Tumor | Endometrial Cancer | Advanced Cancer | Diffuse Midline Glioma, H3 K27M-Mutant | Papillary Thyroid Cancer | Solid Carcinoma | Mesotheliomas Pleural | Glioma, Malignant | Ovary Cancer and other conditions

United States, Australia
Aminex Therapeutics, Inc.

Completed

Oral AMXT 1501 Dicaprate in Combination With DFMO

Cancer | Solid Tumor | Advanced Cancer | Solid Carcinoma

United States
Scilex Pharmaceuticals, Inc.

Completed

Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects

Healthy

United States
Scilex Pharmaceuticals, Inc.

Completed

Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects

Healthy

United States
Scilex Pharmaceuticals, Inc.

Completed

Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects

Healthy

United States
Scilex Pharmaceuticals, Inc.

Completed

Adhesion of Lidocaine Topical System 1.8%

Healthy
Scilex Pharmaceuticals, Inc.

Completed

Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects

Healthy
Scilex Pharmaceuticals, Inc.

Completed

Study to Evaluate the Safety of SP-104

Healthy Volunteers

New Zealand
Scilex Pharmaceuticals, Inc.

Completed

Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure

Healthy

United States
Anulex Technologies, Inc.

Completed

Randomized Study of Anular Repair With the Xclose Tissue Repair System

Diskectomy

United States
Agile Therapeutics

Completed

Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System

Healthy
Agile Therapeutics

Completed

Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers

Healthy

United States
Agile Therapeutics

Completed

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm (ATI-CL13)

Contraception

United States
Scilex Pharmaceuticals, Inc.

Completed

Pharmacokinetics of SP-104

Healthy

New Zealand
Scilex Pharmaceuticals, Inc.

Completed

Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches

Healthy

United States
Scilex Pharmaceuticals, Inc.

Completed

Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects

Healthy
Scilex Pharmaceuticals, Inc.

Completed

Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% Under Conditions of Heat and Exercise

Healthy
Avila Herbals

Unknown

Evaluation of the Safety and Pharmacokinetics of Oleander 4X in Healthy Volunteers

Flu-like Symptoms

United States
Agile Therapeutics

Completed

Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females

Healthy

United States
Agile Therapeutics

Completed

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

Ovulation Suppression

United States
Agile Therapeutics

Completed

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

Contraception

United States
Agile Therapeutics

Completed

Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches (ATI-CL21)

Healthy
Agile Therapeutics

Completed

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

Healthy

United States
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
VIVEX Biologics, Inc.

Terminated

Wound Healing Following Penile Prosthesis Implant

Erectile Dysfunction

United States
Aciex Therapeutics, Inc.

Completed

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Allergic Conjunctivitis

United States
Aciex Therapeutics, Inc.

Completed

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

Healthy

United States
Aciex Therapeutics, Inc.

Completed

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

Atopic Disease (Including Allergic Conjunctivitis)

United States
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Rheumatoid Arthritis

United States, Belgium, United Kingdom
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Yuria-Pharm
Pharmaxi LLC

Completed

Epidemiological Study of the COVID-2019 in Participating Organizations.

Covid19

Ukraine
Aciex Therapeutics, Inc.

Completed

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

Allergic Conjunctivitis

United States
Aciex Therapeutics, Inc.

Completed

A Comparison of the Safety and Comfort of AC-170

Normal Ocular Health

United States
VIVEX Biologics, Inc.

Recruiting

Via Disc Nucleus Pulposus Older Patients Pilot

Low Back Pain | Degenerative Disc Disease | Disc Degeneration

United States
VIVEX Biologics, Inc.

Active, not recruiting

Viable Allograft Supplemented Disc Regeneration in the Treatment of Patients With Low Back Pain (VAST)

Degenerative Disc Disease

United States
Aciex Therapeutics, Inc.

Completed

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Allergic Conjunctivitis

United States
Aciex Therapeutics, Inc.

Completed

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

Allergic Conjunctivitis

United States
Aciex Therapeutics, Inc.

Completed

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model (AC-170)

Allergic Conjunctivitis

United States
Avulux, Inc.
Imarc Research, Inc.

Completed

Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches

Migraine

United States

3

Subscribe